Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
Myriad Genetics (NASDAQ: MYGN) will release its third quarter 2026 financial results after market close on November 4, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN) will release its third quarter 2026 financial results after market close on November 4, 2026. Management will host an earnings conference call at 4:30 pm ET that day to provide a financial overview and business update. A live webcast and subsequent replay will be available on the company’s Investor Relations website.
Details
Market move: MYGN -8.51% in the Oct 16 session. 3Q26 earnings report
On Oct 16, the first trading day after this news, MYGN closed 8.51% below the previous close. Argus tracked a trough of -4.8% from its starting point during tracking. Our momentum scanner recorded 29 alerts for this stock that day.
Data tracked by StockTitan Argus for the Oct 16 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings conference call at 4:30 pm ET on Wednesday, November 4, 2026. The company’s quarterly earnings will be released the same day after market close. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2026.
A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Andria Rosell
(385) 202-3510
PR@myriad.com
